Etanercept with IVIg for acute Kawasaki disease: a long-term follow-up on the EATAK trial.

Background: The Etanercept as Adjunctive Treatment for Acute Kawasaki Disease, a phase-3 clinical trial, showed that etanercept reduced the prevalence of IVIg resistance in acute Kawasaki disease. In patients who presented with coronary artery involvement, it reduced the maximal size and short-term progression of coronary artery dilation. Following up with this patient group, we evaluated the potential long-term benefit of etanercept for coronary disease.

Cognitive-behavioural therapy for children with irritable bowel syndrome.

Question: A child with irritable bowel syndrome (IBS) presented to the clinic with a chief concern of ongoing gastrointestinal symptoms. The parents reported no improvement despite dietary modifications and are not interested in any medications. Is cognitive-behavioural therapy (CBT) an effective treatment for IBS in children?

Answer: Traditional CBT and its subtypes, including Internet-based CBT and gut-directed hypnotherapy, are more effective in reducing pain and gastrointestinal symptoms in children and adolescents with IBS compared with standard treatment or no treatment.